Anavex Life Sciences (12X1) Financial Statements
Anavex Life Sciences Financial Overview
Anavex Life Sciences's market cap is currently $98.44M. The company's EPS TTM is $-0.26; its P/E ratio is -4.55; Anavex Life Sciences has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -51.41M | $ -52.88M | $ -55.76M | $ -50.99M | $ -42.00M |
| EBITDA | $ -46.38M | $ -43.00M | $ -46.54M | $ -47.62M | $ -37.64M |
| Net Income | $ -46.38M | $ -43.00M | $ -47.51M | $ -47.98M | $ -37.91M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 102.58M | $ 132.19M | $ 151.02M | $ 149.16M | $ 152.11M |
| Total Assets | $ 103.81M | $ 135.57M | $ 154.39M | $ 152.70M | $ 161.62M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -102.58M | $ -132.19M | $ -151.02M | $ -149.16M | $ -152.11M |
| Total Liabilities | $ 8.95M | $ 15.30M | $ 12.53M | $ 10.21M | $ 10.80M |
| Stockholders' Equity | $ 94.87M | $ 120.26M | $ 141.85M | $ 142.49M | $ 150.82M |
| Cash Flow | |||||
| Free Cash Flow | $ -39.04M | $ -30.81M | $ -27.79M | $ -24.24M | $ -30.38M |
| Operating Cash Flow | $ -39.04M | $ -30.81M | $ -27.79M | $ -24.24M | $ -30.38M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 9.43M | $ 11.97M | $ 29.65M | $ 21.29M | $ 153.24M |
Currency in USD